Siokas Grigorios's Form 4/A amendment
AmendedCosmos Health Inc. (COSM) · filed Nov 29, 2022
- Accession no.
- 0001477932-22-008938
- Filed
- Nov 29, 2022
- Trade date
- Nov 28, 2022
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not on the form (before 2023)
- Original filed
- Nov 28, 2022
This filing lists 1 non-derivative transaction and 1 derivative transaction. Open-market purchases total $496.8K. It was filed 1 day after the trade.
This amendment replaces 0001477932-22-008924 (filed Nov 28, 2022).
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Siokas GrigoriosCIK 0001660125 | Director, Officer (Chief Executive Officer), 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 28, 2022 | Common Stock, $.001 par value | PPurchaseAcquired | +801,261 | $0.62 | +$496,781.82 | 20,135,429 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 28, 2022 | Common Stock | CConversionDisposed | −1,612,177 | $0.62 | −$308.76 | 1,002 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Mr. Siokas acquired these shares upon conversion of 498 shares of Series A Convertible Preferred Stock ("Series A Shares"), $1,000.00 stated value per share, convertible at $0.62152 per share.
- F2
Mr. Siokas converted the Series A Shares, as set forth in Note (1), above pursuant to a Conversion Notice dated November 28, 2022.
- F3
N/A
- F4
Each Series A Share with a stated value of $1,000.00 per share is convertible at $0.62152 per share.